Inhibition of fatty acid synthase suppresses U-2 OS cell invasion and migration via downregulating the activity of HER2/PI3K/AKT signaling pathway in vitro

Biochemical and Biophysical Research Communications

Volumn 440, Issue 2, 2013, Pages 229-234

  Wang, Tao Fang ^a   Wang, Heng ^a   Peng, Ai Fen ^b   Luo, Qing Feng ^c   Liu, Zhi Li ^a   Zhou, Rong Ping ^a   Gao, Song ^a   Zhou, Yang ^a   Chen, Wen Zhao ^a  

^a NANCHANG UNIVERSITY   (China)

^b JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Cancer Hospital of Jiangxi Province   (China)

Author keywords

Fatty acid synthase (FASN); HER2 PI3K AKT signaling pathway; Invasion; Migration; Osteosarcoma (OS)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; CELL COUNT; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG METASTASIS; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; WOUND HEALING;

FATTY ACID SYNTHASE (FASN); HER2/PI3K/AKT SIGNALING PATHWAY; INVASION; MIGRATION; OSTEOSARCOMA (OS);

CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; FATTY ACID SYNTHASES; HUMANS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84885838177     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.09.024     Document Type: Article

References (29)

1. Laverdiere C., Hoang B.H., Yang R., Sowers R., Qin J., Meyers P.A., Huvos A.G., Healey J.H., Gorlick R. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin. Cancer Res. 2005, 11:2561-2567.
2. Bacci G., Forni C., Longhi A., Ferrari S., Mercuri M., Bertoni F., Serra M., Briccoli A., Balladelli A., Picci P. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J. Surg. Oncol. 2007, 96:118-123.
3. Jawad M.U., Cheung M.C., Clarke J., Koniaris L.G., Scully S.P. Osteosarcoma: improvement in survival limited to high-grade patients only. J. Cancer Res. Clin. Oncol. 2011, 137:597-607.
4. Meyers P.A., Schwartz C.L., Krailo M., Kleinerman E.S., Betcher D., Bernstein M.L., Conrad E., Ferguson W., Gebhardt M., Goorin A.M., Harris M.B., Healey J., Huvos A., Link M., Montebello J., Nadel H., Nieder M., Sato J., Siegal G., Weiner M., Wells R., Wold L., Womer R., Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 2005, 23:2004-2011.
5. Mialou V., Philip T., Kalifa C., Perol D., Gentet J.C., Marec-Berard P., Pacquement H., Chastagner P., Defaschelles A.S., Hartmann O. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome-the French pediatric experience. Cancer 2005, 104:1100-1109.
6. Hegyi M., Semsei A.F., Jakab Z., Antal I., Kiss J., Szendroi M., Csoka M., Kovacs G. Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. Pediatr. Blood Cancer 2011, 57:415-422.
7. Stokkel M.P., Linthorst M.F., Borm J.J., Taminiau A.H., Pauwels E.K. A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. J. Cancer Res. Clin. Oncol. 2002, 128:393-399.
8. Vandhana S., Coral K., Jayanthi U., Deepa P.R., Krishnakumar S. Biochemical changes accompanying apoptotic cell death in retinoblastoma cancer cells treated with lipogenic enzyme inhibitors. Biochim. Biophys. Acta 2013, 1831:1458-1466.
9. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 2006, 66:5977-5980.
10. Migita T., Ruiz S., Fornari A., Fiorentino M., Priolo C., Zadra G., Inazuka F., Grisanzio C., Palescandolo E., Shin E., Fiore C., Xie W., Kung A.L., Febbo P.G., Subramanian A., Mucci L., Ma J., Signoretti S., Stampfer M., Hahn W.C., Finn S., Loda M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J. Natl. Cancer Inst. 2009, 101:519-532.
11. Silva S.D., Cunha I.W., Younes R.N., Soares F.A., Kowalski L.P., Graner E. ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas. Oral Dis. 2010, 16:774-780.
12. Notarnicola M., Pisanti S., Tutino V., Bocale D., Rotelli M.T., Gentile A., Memeo V., Bifulco M., Perri E., Caruso M.G. Effects of olive oil polyphenols on fatty acid synthase gene expression and activity in human colorectal cancer cells. Genes Nutr. 2011, 6:63-69.
13. Zecchin K.G., Rossato F.A., Raposo H.F., Melo D.R., Alberici L.C., Oliveira H.C., Castilho R.F., Coletta R.D., Vercesi A.E., Graner E. Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis. Lab. Invest. 2011, 91:232-240.
14. Yeh C.S., Wang J.Y., Cheng T.L., Juan C.H., Wu C.H., Lin S.R. Fatty acid metabolism pathway play an important role in carcinogenesis of human colorectal cancers by microarray-bioinformatics analysis. Cancer Lett. 2006, 233:297-308.
15. Liu Z.L., Zhou Y., Luo Q.F., Hu M., Wang G., Huang S.H., Shu Y. Inhibition of fatty acid synthase supresses osteosarcoma cell invasion and migration. Indian J. Pathol. Microbiol. 2012, 55:163-169.
16. Liu Z.L., Wang G., Peng A.F., Luo Q.F., Zhou Y., Huang S.H. Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis. Oncol Lett. 2012, 4:878-882.
17. Scotlandi K., Manara M.C., Hattinger C.M., Benini S., Perdichizzi S., Pasello M., Bacci G., Zanella L., Bertoni F., Picci P., Serra M. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur. J. Cancer 2005, 41:1349-1361.
18. Foster H., Knox S., Ganti A.K., Hebert B.J., Koch M., Tendulkar K., Levitt R., Potti A. HER-2/neu overexpression detected by immunohistochemistry in soft tissue sarcomas. Am. J. Clin. Oncol. 2003, 26:188-191.
19. Ma Q., Zhou Y., Ma B., Chen X., Wen Y., Liu Y., Fan Q., Qiu X. The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: a pilot study. Oncol. Lett. 2012, 3:797-801.
20. Vazquez-Martin A., Colomer R., Brunet J., Menendez J.A. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int. J. Oncol. 2007, 31:769-776.
21. Yoon S., Lee M.Y., Park S.W., Moon J.S., Koh Y.K., Ahn Y.H., Park B.W., Kim K.S. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J. Biol. Chem. 2007, 282:26122-26131.
22. Li N., Bu X., Wu P., Huang P. The "HER2-PI3K/Akt-FASN Axis" regulated malignant phenotype of colorectal cancer cells. Lipids 2012, 47:403-411.
23. Puig T., Turrado C., Benhamu B., Aguilar H., Relat J., Ortega-Gutierrez S., Casals G., Marrero P.F., Urruticoechea A., Haro D., Lopez-Rodriguez M.L., Colomer R. Novel inhibitors of fatty acid synthase with anticancer activity. Clin. Cancer Res. 2009, 15:7608-7615.
24. Anninga J.K., van de Vijver M.J., Cleton-Jansen A.M., Kristel P.M., Taminiau A.H., Nooij M., Egeler R.M., Hogendoorn P.C. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur. J. Cancer 2004, 40:963-970.
25. Liu Z.L., Mao J.H., Peng A.F., Yin Q.S., Zhou Y., Long X.H., Huang S.H. Inhibition of fatty acid synthase suppresses osteosarcoma cell invasion and migration via downregulation of the PI3K/Akt signaling pathway in vitro. Mol. Med. Rep. 2013, 7:608-612.
26. Li N., Bu X., Tian X., Wu P., Yang L., Huang P. Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway. Nutr. Cancer 2012, 64:864-870.
27. Corsi F., Fiandra L., De Palma C., Colombo M., Mazzucchelli S., Verderio P., Allevi R., Tosoni A., Nebuloni M., Clementi E., Prosperi D. HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice. ACS Nano 2011, 5:6383-6393.
28. Lin V.C., Chou C.H., Lin Y.C., Lin J.N., Yu C.C., Tang C.H., Lin H.Y., Way T.D. Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway. J. Agric. Food Chem. 2010, 58:4786-4793.
29. Lee J.S., Yoon I.S., Lee M.S., Cha E.Y., Thuong P.T., Diep T.T., Kim J.R. Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells. Biol. Pharm. Bull. 2013, 36:316-325.